NADAC acquisition cost data for BRINZOLAMIDE 1% EYE DROPS. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00591212712 | $14.10 | 2022-12-21 | Rx |
| 00781601485 | $14.10 | 2022-12-21 | Rx |
| 68682046415 | $14.10 | 2022-12-21 | Rx |
| 00591212779 | $18.39 | 2022-12-21 | Rx |
| 00781601470 | $18.39 | 2022-12-21 | Rx |
| 68682046410 | $18.39 | 2022-12-21 | Rx |
| 00591212712 | $14.10 | 2022-12-21 | Rx |
| 00781601485 | $14.10 | 2022-12-21 | Rx |
| 68682046415 | $14.10 | 2022-12-21 | Rx |
| 00591212779 | $18.39 | 2022-12-21 | Rx |
Generic: Brinzolamide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | $35.6M | 97,493 | 37,011 | $25.08 |
| 2022 | $52.8M | 158,498 | 44,494 | $23.90 |
| 2023 | $52.8M | 164,518 | 43,939 | $22.94 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $6.8M | 21,747 | 6,094 |
| New York | $6.3M | 20,882 | 5,424 |
| Texas | $4.7M | 14,581 | 3,900 |
| Florida | $3.6M | 11,364 | 3,148 |
| Pennsylvania | $2.6M | 8,523 | 2,329 |
| New Jersey | $2.4M | 6,829 | 1,893 |
| Michigan | $2.0M | 5,693 | 1,578 |
| Massachusetts | $1.9M | 6,011 | 1,601 |
| Illinois | $1.8M | 5,254 | 1,480 |
| North Carolina | $1.5M | 4,484 | 1,181 |
| Connecticut | $1.2M | 3,484 | 975 |
| Georgia | $1.2M | 3,668 | 1,015 |
| Ohio | $1.2M | 3,451 | 979 |
| Maryland | $1.1M | 3,102 | 941 |
| Virginia | $886.4K | 2,597 | 741 |
| Arizona | $872.8K | 2,479 | 703 |
| Wisconsin | $856.2K | 2,622 | 680 |
| Washington | $834.1K | 2,546 | 699 |
| Puerto Rico | $806.4K | 3,367 | 1,390 |
| Missouri | $786.8K | 2,380 | 650 |
| South Carolina | $668.0K | 2,003 | 569 |
| Indiana | $614.9K | 1,800 | 540 |
| Alabama | $594.0K | 1,847 | 514 |
| Tennessee | $582.1K | 1,731 | 474 |
| Oregon | $562.0K | 1,937 | 558 |
| Minnesota | $547.2K | 1,643 | 433 |
| Louisiana | $510.3K | 1,772 | 449 |
| Colorado | $457.1K | 1,361 | 343 |
| Hawaii | $418.1K | 1,517 | 414 |
| Maine | $387.3K | 1,325 | 344 |
| Iowa | $371.1K | 1,180 | 334 |
| New Hampshire | $285.2K | 867 | 247 |
| Kentucky | $278.4K | 953 | 253 |
| Delaware | $278.3K | 717 | 220 |
| Oklahoma | $270.8K | 929 | 279 |
| Kansas | $223.6K | 768 | 213 |
| Mississippi | $220.2K | 766 | 225 |
| Arkansas | $212.0K | 699 | 177 |
| Rhode Island | $201.0K | 679 | 171 |
| West Virginia | $177.4K | 546 | 151 |
| District of Columbia | $174.7K | 445 | 137 |
| New Mexico | $168.0K | 509 | 137 |
| Nevada | $163.7K | 491 | 141 |
| Utah | $161.6K | 526 | 150 |
| Idaho | $146.1K | 549 | 137 |
| Nebraska | $142.0K | 461 | 120 |
| Vermont | $132.5K | 392 | 102 |
| Montana | $77.4K | 220 | 63 |
| North Dakota | $75.6K | 236 | 66 |
| Alaska | $68.2K | 194 | 49 |
| South Dakota | $55.2K | 197 | 58 |
| Wyoming | $25.2K | 87 | 19 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.